The stock of Fractyl Health Inc. (GUTS) has seen a 9.20% increase in the past week, with a 11.33% gain in the past month, and a -28.93% decrease in the past quarter. The volatility ratio for the week is 11.92%, and the volatility levels for the past 30 days are at 7.79% for GUTS. The simple moving average for the past 20 days is 17.03% for GUTS’s stock, with a -46.52% simple moving average for the past 200 days.
Is It Worth Investing in Fractyl Health Inc. (NASDAQ: GUTS) Right Now?
Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GUTS is 19.88M and currently, short sellers hold a 9.55% of that float. On October 28, 2024, GUTS’s average trading volume was 365.37K shares.
GUTS) stock’s latest price update
Fractyl Health Inc. (NASDAQ: GUTS)’s stock price has plunge by 20.25relation to previous closing price of 2.37. Nevertheless, the company has seen a 9.20% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-28 that BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that it will present compelling weight maintenance data from both its Revita and Rejuva platforms at The Obesity Society’s Annual Meeting at ObesityWeek 2024, held from November 2-6, 2024, in San Antonio, Texas.
Analysts’ Opinion of GUTS
Morgan Stanley, on the other hand, stated in their research note that they expect to see GUTS reach a price target of $18. The rating they have provided for GUTS stocks is “Overweight” according to the report published on February 27th, 2024.
BofA Securities gave a rating of “Buy” to GUTS, setting the target price at $26 in the report published on February 27th of the current year.
GUTS Trading at 3.87% from the 50-Day Moving Average
After a stumble in the market that brought GUTS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.34% of loss for the given period.
Volatility was left at 7.79%, however, over the last 30 days, the volatility rate increased by 11.92%, as shares surge +7.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.81% upper at present.
During the last 5 trading sessions, GUTS rose by +4.21%, in comparison to the 20-day moving average, which settled at $2.43. In addition, Fractyl Health Inc. saw -77.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GUTS starting from Caplan Jay David, who sale 65,000 shares at the price of $2.90 back on Sep 12 ’24. After this action, Caplan Jay David now owns 30,484 shares of Fractyl Health Inc., valued at $188,474 using the latest closing price.
JAY D CAPLAN, the Officer of Fractyl Health Inc., proposed sale 65,000 shares at $2.85 during a trade that took place back on Sep 12 ’24, which means that JAY D CAPLAN is holding shares at $185,213 based on the most recent closing price.
Stock Fundamentals for GUTS
Current profitability levels for the company are sitting at:
- -599.84 for the present operating margin
- -2.67 for the gross margin
The net margin for Fractyl Health Inc. stands at -466.2. The total capital return value is set at -0.54.
Based on Fractyl Health Inc. (GUTS), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -1.57.
Currently, EBITDA for the company is -50.55 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 790.79. The receivables turnover for the company is 5.41for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.46.
Conclusion
To wrap up, the performance of Fractyl Health Inc. (GUTS) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
